The Influence of Tramadol on Platelet Function

Drug Toxicity Clinical Trial

Official title: The Influence of Tramadol on Platelet Function

Status Completed

Clinical Trial Summary

The aim of this ex-vivo study is to quantify the effect of tramadol on platelet aggregation.

Clinical Trial Description

The aim of this study is to quantify the effect of tramadol on platelet aggregation. To this end, the effect of tramadol on platelet function will be demonstrated in an ex-vivo study using optical aggregometry (LTA) on whole blood of 15 patients. The main objective variable is to use platelet function assays (LTA) as well as thrombelastography (TEG) to determine this effect on platelet function. The null hypothesis of this study is that tramadol does not affect platelet aggregation in healthy patients. In addition, two further questions will be addressed: - using a titration series, to attempt to plot a dose/response curve of the effect of tramadol on platelet function. - tramadol is often administered together with other drugs such as NSAIDs (ibuprofen), novalgin, SSRIs or other opioids such as morphine or in the surgical setting fentanyl and remifentanil. A series of studies will be conducted to determine whether these combinations alter the effect of tramadol on platelet function. ;

Related Conditions & MeSH terms

• Blood Coagulation Disorders
• Clotting Disorder
• Drug Toxicity
• Drug-Related Side Effects and Adverse Reactions
• Hemostatic Disorders
• Platelet Dysfunction

• NCT number: NCT05237492
• Study type: Interventional
• Source: Medical University of Graz
• Status: Completed
• Phase: Phase 4
• Start date: January 26, 2022
• Completion date: July 15, 2023